Longeveron Presents at Second Euro-Geroscience Conference
24 March 2022 - 11:00PM
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a
clinical stage biotechnology company developing cellular therapies
for chronic, aging-related and life-threatening conditions,
announced today that management presented at the Second
Euro-Geroscience Conference, being held from March 24-25, 2022
virtually and in Toulouse, France, and at a pre-meeting task force.
The details of Longeveron’s presentations are as
follows:
- Session:
Euro-Geroscience Task Force: “Challenges in Developing Geroscience
Drug Trials”Format: Oral presentation: “Targeting
Frailty with Stem Cells,” presented by Anthony Oliva, Ph.D. Senior
ScientistDate: Wednesday, March 23,
2022Time: 10:30 – 10:50 am CET
- Session: Session
6: “Designing Clinical Trials in
Geroscience”Format: Oral Presentation: “OC23 -
Lomecel-B as a Geroscience Therapeutic Candidate: Clinical Trial
Results” presented by Anthony Oliva, Ph.D. Senior
ScientistDate: Friday, March 25,
2022Time: 4:50 pm CET
About Longeveron Inc.Longeveron
is a clinical stage biotechnology company developing cellular
therapies for specific aging-related and life-threatening
conditions. The Company’s lead investigational product is the
LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is
derived from culture-expanded medicinal signaling cells (MSCs) that
are sourced from bone marrow of young, healthy adult donors.
Longeveron believes that by using the same cells that promote
tissue repair, organ maintenance, and immune system function, it
can develop safe and effective therapies for some of the most
difficult disorders associated with the aging process and other
medical disorders. Longeveron is currently sponsoring Phase 1 and 2
clinical trials in the following indications: Aging Frailty,
Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory
Distress Syndrome (ARDS), and hypoplastic left heart syndrome
(HLHS). The Company’s mission is to advance Lomecel-B and other
cell-based product candidates into pivotal Phase 3 trials, with the
goal of achieving regulatory approvals, subsequent
commercialization, and broad use by the healthcare community.
Additional information about the Company is available at
www.longeveron.com.
Contact:Brendan PayneStern
Investor RelationsTel: (212) 362-1200Email:
Brendan.payne@sternir.com
Source: Longeveron
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jul 2023 to Jul 2024